Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.

Alvarez-Rueda N, Desselle A, Cochonneau D, Chaumette T, Clemenceau B, Leprieur S, Bougras G, Supiot S, Mussini JM, Barbet J, Saba J, Paris F, Aubry J, Birklé S.

PLoS One. 2011;6(9):e25220. doi: 10.1371/journal.pone.0025220.

2.

Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo.

Cochonneau D, Terme M, Michaud A, Dorvillius M, Gautier N, Frikeche J, Alvarez-Rueda N, Bougras G, Aubry J, Paris F, Birklé S.

Cancer Lett. 2013 Jun 10;333(2):194-204. doi: 10.1016/j.canlet.2013.01.032.

PMID:
23370223
3.

Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.

Terme M, Dorvillius M, Cochonneau D, Chaumette T, Xiao W, Diccianni MB, Barbet J, Yu AL, Paris F, Sorkin LS, Birklé S.

PLoS One. 2014 Feb 10;9(2):e87210. doi: 10.1371/journal.pone.0087210. Erratum in: PLoS One. 2014;9(7):e103395.

4.

The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.

Kowalczyk A, Gil M, Horwacik I, Odrowaz Z, Kozbor D, Rokita H.

Cancer Lett. 2009 Aug 28;281(2):171-82. doi: 10.1016/j.canlet.2009.02.040.

PMID:
19339105
5.
6.

Analysis and optimization of interactions between peptides mimicking the GD2 ganglioside and the monoclonal antibody 14G2a.

Horwacik I, Kurciński M, Bzowska M, Kowalczyk AK, Czaplicki D, Koliński A, Rokita H.

Int J Mol Med. 2011 Jul;28(1):47-57. doi: 10.3892/ijmm.2011.655.

PMID:
21455557
7.

Selection of novel peptide mimics of the GD2 ganglioside from a constrained phage-displayed peptide library.

Horwacik I, Czaplicki D, Talarek K, Kowalczyk A, Bolesta E, Kozbor D, Rokita H.

Int J Mol Med. 2007 May;19(5):829-39.

PMID:
17390090
8.

DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.

Bolesta E, Kowalczyk A, Wierzbicki A, Rotkiewicz P, Bambach B, Tsao CY, Horwacik I, Kolinski A, Rokita H, Brecher M, Wang X, Ferrone S, Kozbor D.

Cancer Res. 2005 Apr 15;65(8):3410-8.

9.

Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.

Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, Reisfeld RA.

Cancer Res. 1989 Jun 1;49(11):2857-61.

10.

Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells.

Horwacik I, Durbas M, Boratyn E, Węgrzyn P, Rokita H.

Cancer Lett. 2013 Dec 1;341(2):248-64. doi: 10.1016/j.canlet.2013.08.018.

PMID:
23962557
12.

Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.

Kusano A, Ohta S, Shitara K, Hanai N.

Anticancer Res. 1993 Nov-Dec;13(6A):2207-12.

PMID:
8297135
14.

Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions.

Nakamura K, Tanaka Y, Shitara K, Hanai N.

Cancer Immunol Immunother. 2001 Jul;50(5):275-84.

PMID:
11499811
15.

Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.

Ahmed M, Cheung NK.

FEBS Lett. 2014 Jan 21;588(2):288-97. doi: 10.1016/j.febslet.2013.11.030. Review.

17.

A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies.

Ye JN, Cheung NK.

Int J Cancer. 1992 Jan 21;50(2):197-201.

PMID:
1730513
18.

Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.

Alvarez-Rueda N, Leprieur S, Clémenceau B, Supiot S, Sébille-Rivain V, Faivre-Chauvet A, Davodeau F, Paris F, Barbet J, Aubry J, Birklé S.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5613s-5620s.

19.

Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.

Kawashima I, Yoshida Y, Taya C, Shitara H, Yonekawa H, Karasuyama H, Tada N, Furukawa K, Tai T.

Int J Oncol. 2003 Aug;23(2):381-8.

PMID:
12851687
20.

Distribution of disialoganglioside GD2-antigen and binding of anti-GD2 antibodies on spheroids of neuroblastoma cell line.

Heiss P, Bermatz S, Wehnes H, Heinzmann U, Senekowitsch-Schmidtke R.

Anticancer Res. 1997 Jul-Aug;17(4B):3145-7.

PMID:
9329622

Supplemental Content

Support Center